Added to YB: 2026-09-18
Pitch date: 2026-09-16
BDTX [neutral]
Black Diamond Therapeutics, Inc.
Author Info
No bio for this author
Company Info
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
Market Cap
$113.2M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.45
P/E
-2.65
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Biotech Conferences Week 2 Day 2 Part 1 - Black Diamond Therapeutics, Inc.
BDTX (quick overview): At $1.95, Black Diamond offers a high-upside clinical and M&A profile around silifertinib, a potentially best-in-class, brain-penetrant EGFR inhibitor. In 43 newly diagnosed patients with non-classical EGFR-mutant NSCLC, confirmed ORR was 60%, median PFS exceeded 15 months versus historical median PFS of 8–10 months for afatinib and osimertinib, and the confirmed CNS response rate was 86%. Q4 2026 FDA feedback is crucial because it will determine whether a smaller, faster pivotal route is feasible.
Read full article (2 min)